Wilfried Eberhardt

38.4k total citations · 3 hit papers
239 papers, 7.6k citations indexed

About

Wilfried Eberhardt is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Wilfried Eberhardt has authored 239 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Pulmonary and Respiratory Medicine, 140 papers in Oncology and 37 papers in Molecular Biology. Recurrent topics in Wilfried Eberhardt's work include Lung Cancer Treatments and Mutations (141 papers), Lung Cancer Diagnosis and Treatment (84 papers) and Lung Cancer Research Studies (64 papers). Wilfried Eberhardt is often cited by papers focused on Lung Cancer Treatments and Mutations (141 papers), Lung Cancer Diagnosis and Treatment (84 papers) and Lung Cancer Research Studies (64 papers). Wilfried Eberhardt collaborates with scholars based in Germany, United States and United Kingdom. Wilfried Eberhardt's co-authors include Georgios Stamatis, Martin Stuschke, Filippo de Marinis, Robert Pirker, Joachim von Pawel, Christoph Pöttgen, Kenneth J. O’Byrne, Rodryg Ramlau, Maciej Krzakowski and Jose R. Pereira and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Wilfried Eberhardt

224 papers receiving 7.5k citations

Hit Papers

Cetuximab plus chemothera... 2009 2026 2014 2020 2009 2011 2013 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    2009 1.0k citations Robert Pirker, Jose R. Pereira et al. profile →
  2. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    2011 453 citations Robert Pirker, Jose R. Pereira et al. The Lancet Oncology profile →
  3. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2013 367 citations Wilfried Eberhardt et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Wilfried Eberhardt 5.3k 4.2k 1.7k 895 892 239 7.6k
Thomas E. Stinchcombe 3.7k 0.7× 3.9k 0.9× 1.7k 1.1× 660 0.7× 824 0.9× 215 6.9k
Philip Bonomi 4.4k 0.8× 4.9k 1.2× 2.1k 1.3× 485 0.5× 978 1.1× 241 8.0k
Junming Zhu 4.3k 0.8× 4.1k 1.0× 1.8k 1.1× 431 0.5× 879 1.0× 29 7.3k
Christopher G. Azzoli 7.5k 1.4× 6.0k 1.4× 2.4k 1.4× 1.1k 1.2× 1.4k 1.6× 154 10.2k
David M. Jackman 5.6k 1.1× 4.9k 1.2× 2.0k 1.2× 431 0.5× 1.7k 1.9× 87 7.6k
Masahiko Higashiyama 3.6k 0.7× 2.1k 0.5× 1.5k 0.9× 948 1.1× 947 1.1× 202 6.2k
Rogério Lilenbaum 5.5k 1.0× 5.6k 1.3× 2.1k 1.3× 348 0.4× 1.2k 1.4× 105 8.4k
Alan B. Sandler 3.7k 0.7× 4.5k 1.1× 2.4k 1.5× 394 0.4× 1.0k 1.2× 109 7.5k
Maciej Krzakowski 6.4k 1.2× 7.6k 1.8× 2.2k 1.3× 785 0.9× 1.6k 1.8× 261 11.4k
Kari Chansky 6.7k 1.3× 4.9k 1.2× 1.4k 0.9× 1.2k 1.3× 812 0.9× 83 9.0k

Countries citing papers authored by Wilfried Eberhardt

Since Specialization
Citations

This map shows the geographic impact of Wilfried Eberhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilfried Eberhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilfried Eberhardt more than expected).

Fields of papers citing papers by Wilfried Eberhardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilfried Eberhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilfried Eberhardt. The network helps show where Wilfried Eberhardt may publish in the future.

Co-authorship network of co-authors of Wilfried Eberhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Wilfried Eberhardt. A scholar is included among the top collaborators of Wilfried Eberhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilfried Eberhardt. Wilfried Eberhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sebastian, Martin, Wilfried Eberhardt, Steffen Dörfel, et al.. (2024). Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315). International Journal of Cancer. 154(11). 1967–1978.
3.
Guberina, Maja, Christoph Pöttgen, Nika Guberina, et al.. (2024). Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease. Cancers. 16(6). 1174–1174. 3 indexed citations
4.
Metzenmacher, Martin, Wilfried Eberhardt, Ken Herrmann, et al.. (2024). The Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach: How Much Staging Do We Really Need?. Cancers. 16(10). 1917–1917. 1 indexed citations
5.
Darwiche, Kaid, Michał Seweryn, Vedat Yildiz, et al.. (2021). DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients. European Journal of Cancer. 147. 142–150. 24 indexed citations
6.
Harbeck, Nadia, Andreas Schneeweiß, Peter Thuss‐Patience, et al.. (2021). Neoadjuvant and adjuvant end-points in health technology assessment in oncology. European Journal of Cancer. 147. 40–50. 9 indexed citations
7.
Wiesweg, Marcel, Martin Metzenmacher, Wilfried Eberhardt, et al.. (2021). BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. European Journal of Cancer. 149. 211–221. 12 indexed citations
8.
Stamatis, Georgios, Stefanie Müller, Gerhard Weinreich, et al.. (2021). Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment. European Journal of Cardio-Thoracic Surgery. 61(2). 269–276. 6 indexed citations
9.
Aigner, Clemens, Thomas Brüning, Wilfried Eberhardt, et al.. (2021). Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms – Ein Experten-Konsensuspapier. Pneumologie. 75(10). 776–794. 1 indexed citations
10.
Wiesweg, Marcel, Fabian Mairinger, Henning Reis, et al.. (2020). Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. European Journal of Cancer. 140. 76–85. 37 indexed citations
11.
Guberina, Nika, Christoph Pöttgen, Martin Schüler, et al.. (2020). Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve. European Journal of Cancer. 138. 156–168. 4 indexed citations
12.
Ting, Saskia, Henning Reis, Martin Metzenmacher, et al.. (2020). ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. Lung Cancer. 149. 10–16. 9 indexed citations
13.
Walter, Robert, Balázs Hegedűs, Thomas Hager, et al.. (2020). Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma. Scientific Reports. 10(1). 18677–18677. 17 indexed citations
14.
Wiesweg, Marcel, Thomas Herold, Martin Metzenmacher, et al.. (2019). Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. Lung Cancer. 139. 165–168. 4 indexed citations
15.
Schuette, Wolfgang, Peter Schirmacher, Wilfried Eberhardt, et al.. (2015). EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers & Prevention. 24(8). 1254–1261. 29 indexed citations
16.
Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations
17.
Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2012). Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4794–4805. 55 indexed citations
18.
Pirker, Robert, Jose R. Pereira, Joachim von Pawel, et al.. (2011). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology. 13(1). 33–42. 453 indexed citations breakdown →
19.
Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology. 27(15). 2523–2529. 194 indexed citations
20.
Awada, Ahmad, Jean Klášterský, Christian Stoll, et al.. (2003). Abstracts. British Journal of Cancer. 89(S2). S25–S35. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas E. Stinchcombe Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Junming Zhu Breakdown of academic impact, for papers by Christopher G. Azzoli Breakdown of academic impact, for papers by David M. Jackman Breakdown of academic impact, for papers by Masahiko Higashiyama Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by Alan B. Sandler Breakdown of academic impact, for papers by Maciej Krzakowski Breakdown of academic impact, for papers by Kari Chansky
Rankless by CCL
2026